Crinecerfont enables glucocorticoid dose reductions while maintaining/improving androstenedione in paediatric patients with congenital adrenal hyperplasia: subgroup analyses from CAHtalyst™ paediatric.
Oksana Lekarev, Ayca Erkin-Cakmak, Maria Vogiatzi, Erik Imel, Maria Clemente, Regis Coutant, Thom Board, Gelliza Rosales, Eiry Roberts, George Jeha, Robert Farber, Jean Chan
